CN111295454A - 靶向染色体不稳定性和下游胞质dna信号传导以治疗癌症 - Google Patents

靶向染色体不稳定性和下游胞质dna信号传导以治疗癌症 Download PDF

Info

Publication number
CN111295454A
CN111295454A CN201880058523.8A CN201880058523A CN111295454A CN 111295454 A CN111295454 A CN 111295454A CN 201880058523 A CN201880058523 A CN 201880058523A CN 111295454 A CN111295454 A CN 111295454A
Authority
CN
China
Prior art keywords
cells
cell
cgamp
sample
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880058523.8A
Other languages
English (en)
Chinese (zh)
Inventor
L·C·坎特利
B·恩格
S·F·巴库姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Memorial Sloan Kettering Cancer Center
Original Assignee
Cornell University
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University, Memorial Sloan Kettering Cancer Center filed Critical Cornell University
Publication of CN111295454A publication Critical patent/CN111295454A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
CN201880058523.8A 2017-07-10 2018-07-10 靶向染色体不稳定性和下游胞质dna信号传导以治疗癌症 Pending CN111295454A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530661P 2017-07-10 2017-07-10
US62/530,661 2017-07-10
PCT/US2018/041480 WO2019014246A1 (en) 2017-07-10 2018-07-10 TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
CN111295454A true CN111295454A (zh) 2020-06-16

Family

ID=63036469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880058523.8A Pending CN111295454A (zh) 2017-07-10 2018-07-10 靶向染色体不稳定性和下游胞质dna信号传导以治疗癌症

Country Status (12)

Country Link
US (2) US11821042B2 (cg-RX-API-DMAC7.html)
EP (1) EP3652349A1 (cg-RX-API-DMAC7.html)
JP (1) JP7197556B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200037796A (cg-RX-API-DMAC7.html)
CN (1) CN111295454A (cg-RX-API-DMAC7.html)
AU (1) AU2018300007A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020000477A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069515A1 (cg-RX-API-DMAC7.html)
IL (1) IL271849A (cg-RX-API-DMAC7.html)
MX (1) MX2020000406A (cg-RX-API-DMAC7.html)
SG (1) SG11202000132WA (cg-RX-API-DMAC7.html)
WO (1) WO2019014246A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789180A (zh) * 2016-09-02 2019-05-21 伊利诺伊大学理事会 Kif13b衍生的肽和抑制血管生成的方法
CN113341154A (zh) * 2021-05-14 2021-09-03 医工瑞思(福建)工程研究中心有限公司 一种检测血栓或凝血相关疾病的生物标志物及其应用
CN115354078A (zh) * 2022-09-02 2022-11-18 中山大学附属第一医院 骨肉瘤检测标记物及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11821042B2 (en) 2017-07-10 2023-11-21 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
JP7226763B2 (ja) * 2017-08-17 2023-02-21 国立大学法人山口大学 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法
US20230106899A1 (en) * 2019-06-21 2023-04-06 Ifm Due, Inc. Methods of treating cancer
WO2021167478A1 (en) * 2020-02-19 2021-08-26 Ibmc - Instituto De Biologia Molecular E Celular 4-pyrrolidin-1-yl-5-p-tolyl-thieno[2,3-d] pyrimidine for use in the treatment of aging-associated and premature aging diseases through restored chromosomal stability and inhibition of cellular senescence
CN112113821B (zh) * 2020-05-28 2021-09-03 王剑 一种细胞病理学样本的多重染色制片方法
WO2022051420A1 (en) * 2020-09-02 2022-03-10 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting cytosolic dsdna signaling in chromosomally unstable cancers
US20240207248A1 (en) * 2021-04-23 2024-06-27 Baruch S. Blumberg Institute Methods, kits and compositions for reducing chromosomal instability in cancer cells
KR20240109977A (ko) 2021-08-26 2024-07-12 볼라스트라 쎄라퓨틱스, 인코포레이티드 Kif18a의 스피로 인돌린 억제제
EP4488389A1 (en) * 2023-07-05 2025-01-08 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Signature for the prognosis of brain metastasis relapse

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044790A1 (en) * 2014-09-19 2016-03-24 Memorial Sloan-Kettering Cancer Center Methods for treating brain metastasis
WO2016176222A1 (en) * 2015-04-30 2016-11-03 University Of Washington Cgas in systemic lupus erythematosus (sle)
US20170107577A1 (en) * 2014-03-11 2017-04-20 The Council Of The Queensland Institute Of Medical Research Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
JP2016506408A (ja) * 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
EP3045917A2 (en) * 2013-09-13 2016-07-20 Sierra Jiménez, Angels Marker for predicting metastasis of breast cancer
US11821042B2 (en) 2017-07-10 2023-11-21 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170107577A1 (en) * 2014-03-11 2017-04-20 The Council Of The Queensland Institute Of Medical Research Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment
WO2016044790A1 (en) * 2014-09-19 2016-03-24 Memorial Sloan-Kettering Cancer Center Methods for treating brain metastasis
WO2016176222A1 (en) * 2015-04-30 2016-11-03 University Of Washington Cgas in systemic lupus erythematosus (sle)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDREAS RITTER: "Functional analysis of phosphorylation of the mitotic centromere-associated kinesin by Aurora B kinase in human tumor cells", 《CELL CYCLE》 *
ELENA HEUSINGER: "Primate Lentiviruses Modulate NF-[kappa]B Activity by Multiple Mechanisms to Fine-Tune Viral and Cellular Gene Expressio", 《FRONTIERS IN MICROBIOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789180A (zh) * 2016-09-02 2019-05-21 伊利诺伊大学理事会 Kif13b衍生的肽和抑制血管生成的方法
CN109789180B (zh) * 2016-09-02 2023-09-08 伊利诺伊大学理事会 Kif13b衍生的肽和抑制血管生成的方法
CN113341154A (zh) * 2021-05-14 2021-09-03 医工瑞思(福建)工程研究中心有限公司 一种检测血栓或凝血相关疾病的生物标志物及其应用
CN115354078A (zh) * 2022-09-02 2022-11-18 中山大学附属第一医院 骨肉瘤检测标记物及其应用

Also Published As

Publication number Publication date
AU2018300007A1 (en) 2020-02-27
US20210130903A1 (en) 2021-05-06
US11821042B2 (en) 2023-11-21
US20240110246A1 (en) 2024-04-04
MX2020000406A (es) 2020-10-01
BR112020000477A2 (pt) 2020-07-21
SG11202000132WA (en) 2020-02-27
JP7197556B2 (ja) 2022-12-27
IL271849A (en) 2020-02-27
WO2019014246A1 (en) 2019-01-17
CA3069515A1 (en) 2019-01-17
EP3652349A1 (en) 2020-05-20
JP2020526206A (ja) 2020-08-31
KR20200037796A (ko) 2020-04-09

Similar Documents

Publication Publication Date Title
US20240110246A1 (en) Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
US12247982B2 (en) Markers selectively deregulated in tumor-infiltrating regulatory T cells
US20230203485A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
KR101620642B1 (ko) 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
KR102135601B1 (ko) 탈모 질환의 치료 방법
US20230075965A1 (en) Uses of biomarkers for improving immunotherapy
US20190300967A1 (en) Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
AU2016295347A1 (en) Gene signature for immune therapies in cancer
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
US20230105008A1 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
CN116583537A (zh) 与对过继细胞疗法的应答相关的t细胞表型
US20200300859A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
US11857563B2 (en) Inhibition of expansion and function of pathogenic age-associated B cells and use for the prevention and treatment of autoimmune disease
US20240280561A1 (en) Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
KR20120013992A (ko) 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법
CA3212132A1 (en) Methods of treating red blood cell disorders
JP2024507735A (ja) ブチロフィリンサブファミリー３メンバーａ１（ｂｔｎ３ａ１、ｃｄ２７７）の制御
JP2020536111A (ja) リンパ腫を処置する方法
CA3248094A1 (en) TUMOR CLASSIFICATION AND PREDICTION OF REACTIVITY
CA3023980C (en) Markers selectively deregulated in tumor-infiltrating regulatory t cells
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200616